Cormedix (HAM:19KA) Institutional Ownership: 32.55% (As of Jul. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:19KA Cormedix Inc HAM:19KA
46 GF Score
Price €6.84
GF Value €54.45
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Cormedix Institutional Ownership?

Cormedix HAM:19KA -6.68% 46 Institutional Ownership is 32.55% as of Jul. 22, 2026. GuruFocus rates HAM:19KA with a GF Score™ of 46/100 and a GF Value™ of €54.45 (Possible Value Trap). The stock has 6 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cormedix's institutional ownership is 32.55%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cormedix's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cormedix's Float Percentage Of Total Shares Outstanding is 98.69%.

Cormedix Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Cormedix's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cormedix Institutional Ownership Chart

Cormedix Historical Data

The historical data trend for Cormedix can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 28.85 28.20 28.59 28.41 29.43 29.32 33.02 32.54 32.57 32.55
HAM:19KA
46GF Score
Cormedix Inc HAM:19KA
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cormedix Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 32.55% mean?
Cormedix (HAM:19KA) has a Institutional Ownership of 32.55% as of Jul. 22, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Cormedix and its competitors.
Is Cormedix's Institutional Ownership too high?
Cormedix's current Institutional Ownership is 32.55%. Overall, Cormedix has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cormedix's Institutional Ownership compare to STTK and ACHV?
Cormedix's Institutional Ownership of 32.55% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Cormedix and its competitors. Cormedix's current Institutional Ownership is 32.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cormedix stock overvalued right now?
Based on GuruFocus' analysis, Cormedix (HAM:19KA) is currently considered Possible Value Trap. The stock's GF Value™ is €54.45, compared to a current price of €6.84 — trading 87.4% below its estimated fair value. The current Institutional Ownership is 32.55%. Cormedix's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Cormedix (HAM:19KA), the current Institutional Ownership is 32.55% as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cormedix (HAM:19KA) Overvalued in 2026?

Based on GuruFocus' analysis, Cormedix stock appears to be undervalued. The current stock price of €6.84 is trading 87.4% below its estimated GF Value™ of €54.45. GuruFocus considers Cormedix to be Possible Value Trap.

Key valuation signals for HAM:19KA:

  • Institutional Ownership: 32.55%
  • GF Value™: €54.45 vs. price of €6.84 (87.4% below fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the HAM:19KA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cormedix Business Description

Other Exchanges CRMD:USA19KA:Germany
Address 389 Interpace Parkway, Suite 450, Parsippany, NJ, USA, 07054
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
46GF Score

Get the complete analysis for HAM:19KA

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.84
Price
€54.45
GF Value